Novel vitamin D hydroxyderivatives inhibit melanoma growth and show differential effects on normal melanocytes

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3733-3742

  Slominski, Andrzej T ^a   Janjetovic, Zorica ^a   Kim, Tae Kang ^a   Wright, Adam C ^a   Grese, Laura N ^a   Riney, Samuel J ^a   Nguyen, Minh N ^b   Tuckey, Robert C ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

20 Hydroxyvitamin D derivatives; Melanoma, melanocytes, anti proliferative activity

Indexed keywords

1,20 HYDROXYVITAMIN D3; 20 EPICALCITRIOL; 20 HYDROXYVITAMIN D3; 20,23 DIHYDROXYVITAMIN D3; COLECALCIFEROL DERIVATIVE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CELL CULTURE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; GENE EXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOGENESIS; MELANOMA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; CALCITRIOL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CRICETINAE; HUMANS; MELANOCYTES; MELANOMA; MELANOMA, EXPERIMENTAL; SKIN NEOPLASMS; VITAMINS;

EID: 84866984806     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Bikle DD: Vitamin D metabolism and function in the skin. Mol Cell Endocrinol 347: 80-89, 2011.
2. Brozyna AA, Jozwicki W, Janjetovic Z, and Slominski AT: Expression of vitamin D activating enzyme 1-alpha-hydroxylase (CYP27B1) decreases during melanoma progression. Hum Pathol, In press, 2012. DOI:10.1016/j.humpath.2012.03. 031.
3. Brożyna AA, Jozwicki W, Janjetovic Z and Slominski AT: Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum Pathol 42: 618-631, 2011.
4. Carlberg C and Molnar F: Current status of vitamin D signaling and its therapeutic applications. Curr Top Med Chem 12: 528-547, 2012.
5. 3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 108: 1083-1086, 1981.
6. Denzer N, Vogt T and Reichrath J: Vitamin D receptor (VDR) polymorphisms and skin cancer: A systematic review. Dermatoendocrinol 3: 205-210, 2011.
7. Egan KM: Vitamin D and Melanoma. Annals Epidemiol 19: 455-461, 2009.
8. Finn L, Markovic SN and Joseph RW: Therapy for metastatic melanoma: the past, present, and future. BMC Med 10: 23, 2012.
9. Flaherty KT: Targeting metastatic melanoma. Annu Rev Med 63: 171-183, 2012.
10. Flaherty KT, Hodi FS and Fisher DE: From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12: 349-361, 2012.
11. 3: unique hydroxylated metabolites formed during catalysis with cytochrome P450scc (CYP11A1). Proc Natl Acad Sci USA 100: 14754-14759, 2003.
12. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y and Sznol M: PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 23: 190-200, 2010.
13. Holick MF: Vitamin D deficiency. N Engl J Med 357: 266-281, 2007.
14. 3 derivatives. Br J Cancer 105: 1874-1884, 2011.
15. 3, novel P450scc product, stimulates differentiation and inhibits proliferation and NF-kappaB activity in human keratinocytes. J Cell Physiol 223: 36-48, 2010.
16. 3 hydroxylation by P450scc, decreases NFkappaB activity by increasing IkappaB alpha levels in human keratinocytes. PLoS One 4: e5988, 2009.
17. Kim TK, Chen J, Li W, Zjawiony J, Miller D, Janjetovic Z, Tuckey RC and Slominski A: A new steroidal 5,7-diene derivative, 3beta-hydroxyandrosta-5,7- diene-17beta-carboxylic acid, shows potent anti-proliferative activity. Steroids 75: 230-239, 2010.
18. Kim TK, Wang J, Janjetovic Z, Chen J, Tuckey RC, Nguyen MN, Tang EK, Miller D, Li W and Slominski AT: Correlation between secosteroid-induced vitamin D receptor activity in melanoma cells and computer-modeled receptor binding strength. Mol Cell Endocrinol: In press, 2012. DOI:10.1016/j.mce.2012.04.001.
19. 3, which shows antiproliferative activity. Steroids 75: 926-935, 2010.
20. Mansur CP, Gordon PR, Ray S, Holick MF and Gilchrest BA: Vitamin D, its precursors, and metabolites do not affect melanization of cultured human melanocytes. J Invest Dermatol 91: 16-21, 1988.
21. Pinczewski J and Slominski A: The potential role of vitamin D in the progression of benign and malignant melanocytic neoplasms. Exp Dermatol 19: 860-864, 2010.
22. Pisarchik A and Slominski AT: Alternative splicing of CRH-R1 receptors in human and mouse skin: identification of new variants and their differential expression. FASEB J 15: 2754-2756, 2001.
23. Plum LA and DeLuca HF: Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov 9: 941-955, 2010.
24. Ribas A, Hersey P, Middleton MR, Gogas H, Flaherty KT, Sondak VK and Kirkwood JM: New challenges in endpoints for drug development in advanced melanoma. Clin Cancer Res 18: 336-341, 2012.
25. Slominski A, Moellmann G, Kuklinska E, Bomirski A and Pawelek J: Positive regulation of melanin pigmentation by two key substrates of the melanogenic pathway, L-tyrosine and L-dopa. J Cell Sci 89(Pt 3): 287-296, 1988. (Pubitemid 18094890)
26. Slominski A, Semak I, Wortsman J, Zjawiony J, Li W, Zbytek B and Tuckey RC: An alternative pathway of vitamin D metabolism. Cytochrome P450scc (CYP11A1)-mediated conversion to 20-hydroxyvitamin D2 and 17,20-dihydroxyvitamin D2. FEBS J 273: 2891-2901, 2006.
27. Slominski A, Semak I, Zjawiony J, Wortsman J, Li W, Szczesniewski A and Tuckey RC: The cytochrome P450scc system opens an alternate pathway of vitamin D3 metabolism. FEBS J 272: 4080-4090, 2005. (Pubitemid 41160916)
28. Slominski A, Tobin DJ, Shibahara S and Wortsman J: Melanin Pigmentation in Mammalian Skin and Its Hormonal Regulation. Physiol Rev 84: 1155-1228, 2004. (Pubitemid 39287950)
29. Slominski A, Zbytek B and Slominski R: Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells. Int J Cancer 124: 1470-1477, 2009.
30. 3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activity. PLoS One 5: e9907, 2010.
31. 3 metabolism initiated by P450scc and modified by CYP27B1. FASEB J doi: 10.1096/fj.12-208975. 2012.
32. 2 is a noncalcemic analog of vitamin D with potent anti-proliferative and prodifferentiation activities in normal and malignant cells. Am J Cell Physiol 300: C526-541, 2011.
33. Slominski AT, Zmijewski MA, Semak I, Sweatman T, Janjetovic Z, Li W, Zjawiony JK and Tuckey RC: Sequential metabolism of 7-dehydrocholesterol to steroidal 5,7-dienes in adrenal glands and its biological implication in the skin. PLoS One 4: e4309, 2009.
34. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK and Ribas A: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707-714, 2012.
35. Spina CS, Tangpricha V, Uskokovic M, Adorinic L, Maehr H and Holick MF: Vitamin D and cancer. Anticancer Res 26: 2515-2524, 2006. (Pubitemid 44155530)
36. Szyszka P, Zmijewski MA and Slominski AT: New vitamin D analogs as potential therapeutics in melanoma. Expert Rev Anticancer Ther 12: 585-599, 2012.
37. 3 1alpha-hydroxylase (CYP27B1). J Steroid Biochem Mol Biol 119: 171-179, 2010.
38. 3 incorporated into phospholipid vesicles by human CYP27A1. J Steroid Biochem Mol Biol 129: 163-171, 2012.
39. 3. J Steroid Biochem Mol Biol 2008.
40. 3 by cytochrome p450scc (CYP11A1) and analysis of their biological activities on skin cells. Drug Metab Dispos 39: 1577-1588, 2011.
41. 3 by cytochrome P450scc. FEBS J 275: 2585-2596, 2008.
42. Wang J, Slominski A, Tuckey RC, Janjetovic Z, Kulkarni A, Chen J, Postlethwaite AE, Miller D and Li W: 20-hydroxyvitamin D inhibits proliferation of cancer cells with high efficacy while being non-toxic. Anticancer Res 32: 739-746, 2012.
43. 3 hydroxylation by cytochrome P450scc, stimulates keratinocyte differentiation. J Invest Dermatol 128: 2271-2280, 2008.